Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease

Fabrizio Villani, Alessandra Busia, Massimiliano Villani, Chiara Vismara, Simonetta Viviani, Valeria Bonfante

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aims and background. Mediastinal radiotherapy and multiple-drug chemotherapy, including bleomycin employed in the treatment of Hodgkiris disease, can produce lung toxicity leading to fibrosis. There is increasing evidence of the involvement in the fibrosing process of different cytokines and growth factors such as TNF-alfa, IL-1 beta, TGF-beta and PDGF. Material and methods. In a pilot study, we evaluated lung function in 20 patients suffering from Hodgkin's disease, mainly in stage II A, submitted to multiple-drug chemotherapy including bleomycin (ABVD) and mediastinal radiotherapy and correlated its modifications with serum concentration of the cytokines determined by immunoenzymatic assay. Spirometry and transfer lung function for carbon monoxide (DLCO) were performed before, at the end of chemotherapy, at the end of radiotherapy and after a follow-up of 6 and 12 months. Results. DLCO decreased at the end of the combined treatment and then remained constantly decreased. TNF-alfa, TGF-beta and PDGF-alfa concentrations did not change, whereas IL-I beta significantly increased after the completion of the combined treatment and after a follow-up of 6-months and then declined to normal values after 12 months. The serum concentration of the cytokine was significantly higher in patients who had a DLCO 75%. Conclusions. The results indicate a potential role of IL-1 beta in the pathogenesis of chemoradiotherapy-induced lung toxicity, which needs to be confirmed in a larger patient population.

Original languageEnglish
Pages (from-to)803-808
Number of pages6
JournalTumori
Volume94
Issue number6
Publication statusPublished - Nov 2008

Fingerprint

Hodgkin Disease
Radiotherapy
Cytokines
Lung
Serum
Interleukin-1beta
Drug Therapy
Transforming Growth Factor beta
Tumor Necrosis Factor-alpha
Spirometry
Bleomycin
Chemoradiotherapy
Carbon Monoxide
Pharmaceutical Preparations
Intercellular Signaling Peptides and Proteins
Reference Values
Fibrosis
Therapeutics
Population

Keywords

  • Cytokines
  • Hodgkin's disease
  • Lung toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Villani, F., Busia, A., Villani, M., Vismara, C., Viviani, S., & Bonfante, V. (2008). Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori, 94(6), 803-808.

Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. / Villani, Fabrizio; Busia, Alessandra; Villani, Massimiliano; Vismara, Chiara; Viviani, Simonetta; Bonfante, Valeria.

In: Tumori, Vol. 94, No. 6, 11.2008, p. 803-808.

Research output: Contribution to journalArticle

Villani, F, Busia, A, Villani, M, Vismara, C, Viviani, S & Bonfante, V 2008, 'Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease', Tumori, vol. 94, no. 6, pp. 803-808.
Villani F, Busia A, Villani M, Vismara C, Viviani S, Bonfante V. Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori. 2008 Nov;94(6):803-808.
Villani, Fabrizio ; Busia, Alessandra ; Villani, Massimiliano ; Vismara, Chiara ; Viviani, Simonetta ; Bonfante, Valeria. / Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. In: Tumori. 2008 ; Vol. 94, No. 6. pp. 803-808.
@article{691e2e1e17864b61868b325b7056e8fa,
title = "Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease",
abstract = "Aims and background. Mediastinal radiotherapy and multiple-drug chemotherapy, including bleomycin employed in the treatment of Hodgkiris disease, can produce lung toxicity leading to fibrosis. There is increasing evidence of the involvement in the fibrosing process of different cytokines and growth factors such as TNF-alfa, IL-1 beta, TGF-beta and PDGF. Material and methods. In a pilot study, we evaluated lung function in 20 patients suffering from Hodgkin's disease, mainly in stage II A, submitted to multiple-drug chemotherapy including bleomycin (ABVD) and mediastinal radiotherapy and correlated its modifications with serum concentration of the cytokines determined by immunoenzymatic assay. Spirometry and transfer lung function for carbon monoxide (DLCO) were performed before, at the end of chemotherapy, at the end of radiotherapy and after a follow-up of 6 and 12 months. Results. DLCO decreased at the end of the combined treatment and then remained constantly decreased. TNF-alfa, TGF-beta and PDGF-alfa concentrations did not change, whereas IL-I beta significantly increased after the completion of the combined treatment and after a follow-up of 6-months and then declined to normal values after 12 months. The serum concentration of the cytokine was significantly higher in patients who had a DLCO 75{\%}. Conclusions. The results indicate a potential role of IL-1 beta in the pathogenesis of chemoradiotherapy-induced lung toxicity, which needs to be confirmed in a larger patient population.",
keywords = "Cytokines, Hodgkin's disease, Lung toxicity",
author = "Fabrizio Villani and Alessandra Busia and Massimiliano Villani and Chiara Vismara and Simonetta Viviani and Valeria Bonfante",
year = "2008",
month = "11",
language = "English",
volume = "94",
pages = "803--808",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease

AU - Villani, Fabrizio

AU - Busia, Alessandra

AU - Villani, Massimiliano

AU - Vismara, Chiara

AU - Viviani, Simonetta

AU - Bonfante, Valeria

PY - 2008/11

Y1 - 2008/11

N2 - Aims and background. Mediastinal radiotherapy and multiple-drug chemotherapy, including bleomycin employed in the treatment of Hodgkiris disease, can produce lung toxicity leading to fibrosis. There is increasing evidence of the involvement in the fibrosing process of different cytokines and growth factors such as TNF-alfa, IL-1 beta, TGF-beta and PDGF. Material and methods. In a pilot study, we evaluated lung function in 20 patients suffering from Hodgkin's disease, mainly in stage II A, submitted to multiple-drug chemotherapy including bleomycin (ABVD) and mediastinal radiotherapy and correlated its modifications with serum concentration of the cytokines determined by immunoenzymatic assay. Spirometry and transfer lung function for carbon monoxide (DLCO) were performed before, at the end of chemotherapy, at the end of radiotherapy and after a follow-up of 6 and 12 months. Results. DLCO decreased at the end of the combined treatment and then remained constantly decreased. TNF-alfa, TGF-beta and PDGF-alfa concentrations did not change, whereas IL-I beta significantly increased after the completion of the combined treatment and after a follow-up of 6-months and then declined to normal values after 12 months. The serum concentration of the cytokine was significantly higher in patients who had a DLCO 75%. Conclusions. The results indicate a potential role of IL-1 beta in the pathogenesis of chemoradiotherapy-induced lung toxicity, which needs to be confirmed in a larger patient population.

AB - Aims and background. Mediastinal radiotherapy and multiple-drug chemotherapy, including bleomycin employed in the treatment of Hodgkiris disease, can produce lung toxicity leading to fibrosis. There is increasing evidence of the involvement in the fibrosing process of different cytokines and growth factors such as TNF-alfa, IL-1 beta, TGF-beta and PDGF. Material and methods. In a pilot study, we evaluated lung function in 20 patients suffering from Hodgkin's disease, mainly in stage II A, submitted to multiple-drug chemotherapy including bleomycin (ABVD) and mediastinal radiotherapy and correlated its modifications with serum concentration of the cytokines determined by immunoenzymatic assay. Spirometry and transfer lung function for carbon monoxide (DLCO) were performed before, at the end of chemotherapy, at the end of radiotherapy and after a follow-up of 6 and 12 months. Results. DLCO decreased at the end of the combined treatment and then remained constantly decreased. TNF-alfa, TGF-beta and PDGF-alfa concentrations did not change, whereas IL-I beta significantly increased after the completion of the combined treatment and after a follow-up of 6-months and then declined to normal values after 12 months. The serum concentration of the cytokine was significantly higher in patients who had a DLCO 75%. Conclusions. The results indicate a potential role of IL-1 beta in the pathogenesis of chemoradiotherapy-induced lung toxicity, which needs to be confirmed in a larger patient population.

KW - Cytokines

KW - Hodgkin's disease

KW - Lung toxicity

UR - http://www.scopus.com/inward/record.url?scp=61349124871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349124871&partnerID=8YFLogxK

M3 - Article

C2 - 19267096

AN - SCOPUS:61349124871

VL - 94

SP - 803

EP - 808

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -